Document is current

Article History

Received: 2 July 2021

Accepted: 16 February 2022

First Online: 7 April 2022

Competing interests

: M.L.T.: advisory role: AbbVie, Aduro, Blueprint Medicines Celgene, Daiichi Sankyo, Genentech, G1 Therapeutics, Immunomedics, Lilly, Merck & Co., Natera, OncoSec Medical, Pfizer. Institutional research funding from AbbVie, AstraZeneca, Bayer, Biothera, Calithera, EMD Serono, Billerica, MA USA, Genentech, Merck & Co., OncoSec Medical, Pfizer, PharmaMar, Tesaro, Vertex. S.M.T.: Institutional research funding from AstraZeneca, Lilly, Merck & Co., Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck & Co., Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, AbbVie, Anthenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, Gilead, and Samsung Bioepsis Inc. G.I.S. has received research funding from Eli Lilly, the healthcare business of EMD Serono, Billerica, MA USA, Merck & Co., and Sierra Oncology. He has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, the healthcare business of EMD Serono, Billerica, MA USA, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalis and CytomX Therapeutics. In addition, he holds a patent entitled, “Dosage regimen for sapacitabine and seliciclib,” also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,” together with Liam Cornell. M.M.: personal fees from Amgen, grants and personal fees from Roche, grants from AstraZeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millenium, personal fees, non-financial support and other from Immunocore, personal fees and other from BMS and Eisai, other from Pfizer, personal fees, non-financial support and other from MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, personal fees from Kineta, and personal fees from Silicon Therapeutics, outside the submitted work. S.R.L.: personal fees from Eisai, Shionogi and Prosigna, and was previously employed by Pfizer, research funding from Pathios Therapeutics, received travel, accommodation or expenses from Pfizer, Roche, Synthon and Piqur Therapeutics, cofounder and stock holding in Mitox Therapeutics. H.-T.A. has served as an advisor/consultant for Bicycle Therapeutics, Biontech, Bayer, Beigene, Servier, Roche and Guardant Health, and honoraria from Bicycle Therapeutics, Biontech, Bayer, Beigene, Servier, Roche and Guardant Health. A.T.: AstraZeneca-Financial support to academic and hospital institutions for costs associated with academic study chair and local site costs for OlympiA trial/Travel expenses related to any trial related travel/Payments to Institution through Breast International Group for trial conduct in Olympia trial and through CRO’s for commercial PARP inhibitor trials AstraZeneca with royalties paid by Institute of Cancer Research with royalties paid for use of PARP inhibitors in DNA deficient cancers, licensee - AstraZeneca. Payments to Institute of Cancer Research and personally through ICR rewards to Inventors scheme. the healthcare business of Merck KGaA, Darmstadt, Germany: local site trial support costs associated with clinical trial. Pfizer: personal fees/Advisory Board related to targeted therapies in DNA repair deficient cancers. Vertex: personal fees from/Advisory Board related to targeted therapies in DNA repair deficient. Artios: personal fees/Advisory Board related to targeted therapies in DNA repair deficient cancers. Prime Oncology-Personal fees/Advisory Board related to targeted therapies in DNA repair deficient cancers. Medivation: financial support for research at ICR. Breast Cancer Now Charity: grant funded to study homologous recombination deficient breast and other cancers, BCN receive payments through AstraZeneca related to PARP inhibitor patents. CRUK: grant funded to study homologous recombination deficient breast and other cancers, CRUK receive payments through AstraZeneca related to PARP inhibitor patents/personal fees/honoraria associated with function as Deputy Chair and reviewer for CRUK Clinical Research committee. Inbiomotion: personal fees/Scientific Ad Board function and stock options. MD Anderson: personal fees/Moon shot Breast Cancer scientific advisory board honoraria. Medscape Education honorarium from Merck & Co. educational grant: personal fees/speaker for a video series. V.A. has received consulting fees from Daiichi Sankyo and Eisai and research grants from Genentech. E.D. was an employee and stockholder at AstraZeneca subsequent to involvement in this study. T.C.H. has received research funding from Takeda Oncology. R.W. has received research funding from Acerta Pharma and AstraZeneca; served on advisory boards for Puma Biotechnology, Pfizer; and served on speakers’ bureau for Roche Diagnostics. J.F.-P. is an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. T.Go. and T.Gr. are employees of the healthcare business of Merck KGaA, Darmstadt, Germany. J.D. is an employee of EMD Serono, Billerica MA, USA. P.F.-M.: an employee of EMD Serono, Billerica MA, USA. I.D.-P. was an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, at the time of the study and is currently an employee of GlaxoSmithKline, Zug, Switzerland. R.P. has received honoraria for attending advisory boards from Pierre Faber, Bayer, Octimet, Clovis Oncology, Novartis, Karus Therapeutics, Biosceptre, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics and Sanofi Aventis. Fees for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer, Tesaro and BMS. Funds to support attendance at conferences from BMS and MSD.